https://mp.weixin.qq.com/s/nvbd6Khs-PPpVoFw1Dv5sQ

我打了 Pfizer辉瑞制药公司新冠试验疫苗之后......

本文作者具有医检师和护士背景,她以亲身经历告诉读者:她今年参与了美国辉瑞制药公司新冠疫苗第三阶段人体测试经历,描述了注射疫苗之后的人体反应和问题。本文值得一读。

https://mp.weixin.qq.com/s/nvbd6Khs-PPpVoFw1Dv5sQ
Past 31 days
Total Visit: 0
There is 1 fact-checking reply to the message
Pei-Chi Lo mark this message contains personal perspective
originally written by Pei-Chi Lo
■以下資訊皆正確:

①Pfizer與BioNTech合作開發的候選疫苗BNT162b2的確已進行第2/3期臨床試驗,試驗中的疫苗注射的確是兩劑、也的確有安慰劑的對照組。

②初步有效性分析顯示,施打第一劑後28天內有超過95%的有效性,此有效性在不同年齡、性別、種族皆一致。

③兩公司的確表示將向美國政府申請緊急使用授權(EUA),預期在2020年底前將能生產5千萬劑疫苗。
 
④該疫苗的數據監測委員會迄今(2020年12月7日)尚未通報任何嚴重的安全性問題,僅有暫時性的副作用,例如施打第二劑後副作用的比例頭痛約2%、疲勞約3.8%

■但需留意:轉傳訊息中所提的注射後反應為作者個人感受,無法證實是施打疫苗後的反應,亦有可能是受「安慰劑效應」影響。

Opinion Sources

Pfizer與BioNTech疫苗註冊的臨床試驗資訊:
https://clinicaltrials.gov/ct2/show/NCT04368728?term=vaccine&cond=covid-19&draw=3

BioNTech官網-COVID-19疫苗資訊介紹:
https://biontech.de/covid-19

Pfizer官網-COVID-19疫苗資訊介紹:
https://www.pfizer.com/science/coronavirus/vaccine

Pfizer 2020年11月18日新聞稿-Pfizer And Biontech Conclude Phase 3 Study Of Covid-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints:
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine

安慰劑效應說明:
https://scitechvista.nat.gov.tw/c/sKJn.htm

Global COVID-19 vaccine development program Lightspeed

In an effort to address the global health crisis, we are developing a COVID-19 vaccine candidate based on our proprietary mRNA technology. Find out more about our development process, mRNA-based vacci

https://biontech.de/covid-19

The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.

Add Cofacts as friend in LINE
Add Cofacts as friend in LINE
LINE 機器人
查謠言詐騙